Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Porto – page 22

489 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Porto at a glance
489
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

489 trials in Porto

Open in trial search

Aplastic anaemia+1

Not recruiting

A Study Comparing Eltrombopag Tablets in Healthy Volunteers to Test if Two Forms of the Medicine Work the Same Way in the Body After Taking with Food

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Endometrial cancer+2

Not recruiting

A study comparing how lenvatinib capsules are absorbed in the body in healthy volunteers under fasting and fed conditions

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Lenvatinib
  • Sponsor:Bluepharma Industria Farmaceutica S.A.

Neovascular age-related macular degeneration

Not recruiting

A study comparing 4D-150 and aflibercept for adults with abnormal blood vessel growth in the eye due to age-related macular degeneration

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:4d Molecular Therapeutics Inc.

Chronic kidney disease

Not recruiting

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Empagliflozin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Anxiety+1

Not recruiting

Comparison of Oxazepam 50 mg orodispersible tablets and Oxazepam 50 mg standard tablets in healthy volunteers to test if they work the same way in the body

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Oxazepam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Nicotine dependence

Not recruiting

Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cytisinicline
  • Sponsor:Achieve Life Sciences Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

  • Vision disorders
  • Genetic disorders
  • Treatment efficacy studies
02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

  • Blood cancers
  • Solid tumors
  • Immunotherapy
03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

  • Inflammatory skin conditions
  • Autoimmune disorders
  • Novel biologics
04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

  • Heart conditions
  • Metabolic diseases
  • Weight management
05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

  • Neurological disorders
  • Rare diseases
  • Pain management
Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.